Deciphera Pharmaceuticals, Inc. (DCPH) CEO Steve Hoerter on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 02/09/22
Deciphera Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2021 Financial ResultsBusiness Wire • 02/08/22
Analysts Estimate Deciphera Pharmaceuticals, Inc. (DCPH) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 02/01/22
Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call and Webcast on February 8, 2022Business Wire • 02/01/22
Deciphera Pharmaceuticals Presents Results from the INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series SessionBusiness Wire • 01/24/22
Deciphera Pharmaceuticals Provides Corporate Update and Highlights Key 2022 Corporate MilestonesBusiness Wire • 01/10/22
Deciphera Pharmaceuticals, Inc. to Present at the 40th Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 01/03/22
Deciphera Announces Approval of QINLOCK® in the United Kingdom for the Treatment of Fourth-Line Gastrointestinal Stromal TumorBusiness Wire • 12/21/21
Why Is Deciphera Pharmaceuticals, Inc. (DCPH) Down 78.5% Since Last Earnings Report?Zacks Investment Research • 12/02/21
Deciphera Pharmaceuticals Is Trying to Beat Financial Cancer — And Losing HardInvestorPlace • 11/30/21
Deciphera Pharmaceuticals Announces Restructuring to Prioritize Clinical Development Programs and Streamline Commercial OperationsBusiness Wire • 11/30/21
Deciphera Receives European Commission Approval of QINLOCK® for the Treatment of Fourth-Line Gastrointestinal Stromal TumorBusiness Wire • 11/22/21